NCT01179776

Ilomedin Treatment for Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)

A Single Center, Open, Randomized, Placebo-controlled Study Investigating the Safety of Administration of Ilomedin® in Addition to Standard Treatment in Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Thrombologic ApS · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Acute myocardial infarct patients with STEMI (ST-elevation on ECG) whom undergo a primary percutaneous cardiac intervention will following the standard treatment , received low dose of Ilomedin and to low dose of standard treatment for another 24 hours.

Conditions

• Myocardial Infarct

Interventions

Type	Name	Description
DRUG	Ilomedin	Ilomedin
DRUG	Placebo	i.v saline
DRUG	Ilomedin
DRUG	Ilomedin and standard low dose treatment

Timeline

• Start date: 2010-09-01
• Primary completion: 2011-05-01
• Completion: 2011-06-01
• First posted: 2010-08-11
• Last updated: 2011-06-02

Locations

1 site across 1 country: Denmark